Aquestive Pharma (AQST): Analyst Target Range

Corporate company logo of Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics (AQST) is a niche pharmaceutical business whose development relies on FDA approval and the market launch of adrenaline strips. Production is automated, with robots in sterile facilities precisely cutting and packaging polymer films. This historical price chart featuring the 9.37 metric complements data on the patent protection of PharmFilm technologies, which create significant barriers to entry for competitors in the epilepsy therapy segment.

Aquestive Corp (AQST): Consensus Target from 07/04/2022 to 11/12/2026
Flagship merchandise of Aquestive Corp

To preserve capital during periods of volatility, it is critical for investors to identify an asset's overheating point. The consensus forecast aggregates expert estimates to determine a company's fair value relative to current quotes. By analyzing the weighted average target price of a security, investors can lock in profits as the market converges with the calculated limit. For Aquestive Therapeutics (AQST), this indicator reflects capitalization potential driven by the diversification of its innovative medicinal film portfolio.

Competitors of Aquestive Therapeutics

Analyst Consensus Forecast haleon.com (HLN)|Price Target Chart Kenvue KVUE|Analyst Target Range Verona Pharma PLC|MENS - Price Target Chart|Analyst Median Target Ligand Corp LGND|AMRX (Amneal Pharmaceuticals) - Consensus Target|PRGO: Analyst Forecast Prices|Price Target Chart Alvotech SA|Liquidia Corp - Forecast Levels Chart|Analyst Consensus Forecast GLPG|ANIP (ANI Pharmaceuticals Corp) - Fair Value Consensus|Analyst Consensus Forecast MNKD (MannKind Corporation)|Analyst Consensus Forecast amphastar.com AMPH|PCRX - Price Target Chart|Fair Value Consensus SPRY (ARS Pharmaceuticals Inc)|Theravance (TBPH) - Price Target Chart|Consensus Target scPharmaceuticals|TECX (Tectonic Therapeutic Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast tonixpharma.com|Consensus Target SXTC (China SXT Pharmaceuticals)|EPRX (eupraxiapharma.com) - Fair Value Consensus|Price Target Chart BioHarvest BHST|Invizyne (EXOZ) - Average Forecast Price|ORMP: Consensus Target|Entera Bio Ltd. - Analyst Forecast Prices|HYFT: Analyst Consensus Forecast|ABVC BioPharma Inc. - Fair Value Consensus|CPIX (Cumberland Pharma) - Analyst Consensus Forecast|Average Forecast Price Quantum BioPharma Corp QNTM|Price Target Chart FibroGen, Inc. (FGEN)|TELO (telomirpharma.com) - Fair Value Consensus|Analyst Consensus Forecast RANI (Rani Therapeutics Holdings, Inc.)|Analyst Consensus Forecast Synergy CHC Corp. SNYR|RLYB - Price Target Chart|Analyst Target Range Lexaria Bioscience (LEXX)|PULM (Pulmatrix, Inc.) - Consensus Target|Pheton Holdings (PTHL) - Analyst Consensus Forecast|APM (Aptorum Group Ltd) - Analyst Consensus Forecast|Average Forecast Price Lyra Therapeutics Inc. LYRA|Price Target Chart Impact BioMedical Inc (IBO)|Analyst Median Target tnfpharma.com|cbdMD - Consensus Target|Analyst Forecast Prices PRFX (painreform.com)|Auris Medical - Analyst Consensus Forecast|Analyst Median Target Lipella Pharmaceuticals Inc LIPO|OPTN (Optinose) - Consensus Target|PIRS (Pieris Pharma) - Price Target Chart|PROC (Procaps Group S.A.) - Analyst Consensus Forecast|Average Forecast Price petrospharma.com PTPI|Consensus Target QLI (Qilian International Holding)|SLRN (Acelyrin Inc.) - Fair Value Consensus|TFF Pharma - Consensus Target